A drug called sotagliflozin prevented heart thickening and improved heart function in mice with hypertrophic cardiomyopathy, according to a 2026 study published in the Journal of Molecular and Cellular Cardiology Plus. The drug restored normal mitochondrial gene activity and reduced oxidative stress in heart cells. While these results are promising, human clinical trials are needed before this treatment can be used in patients
Researchers tested a drug called sotagliflozin on mice with hypertrophic cardiomyopathy, a genetic condition that makes the heart muscle thick and stiff. According to Gram Research analysis, the drug prevented the heart from getting worse, reduced scarring, and fixed problems with how the heart relaxes. The treatment also improved how mitochondria (the energy factories inside heart cells) work and reduced harmful molecules called free radicals. While these results are exciting, the study was only done in mice, so more testing in humans is needed before doctors can prescribe this drug for patients.
Key Statistics
A 2026 mouse study found that sotagliflozin prevented further left ventricular hypertrophy and normalized diastolic function in mice with hypertrophic cardiomyopathy caused by the E180G genetic mutation after 8 weeks of treatment.
According to research reviewed by Gram, sotagliflozin upregulated mitochondrial gene sets and prevented the increase in oxidative stress in diseased mouse hearts, suggesting the drug works by restoring cellular energy production.
In the 2026 study, sotagliflozin treatment decreased interstitial fibrosis and reduced atrial size in mice with genetic hypertrophic cardiomyopathy compared to untreated controls.
The Quick Take
- What they studied: Whether a drug called sotagliflozin could help mice with a genetic heart disease that causes the heart muscle to thicken abnormally
- Who participated: Young mice (7-8 weeks old) that either had the genetic mutation causing heart thickening or were normal controls. Some mice received the drug in their food, while others ate regular food for 8 weeks
- Key finding: Mice treated with sotagliflozin for 8 weeks stopped getting worse. Their hearts didn’t thicken further, scarring decreased, the heart’s relaxation improved, and the energy-making parts of heart cells worked better
- What it means for you: This research suggests sotagliflozin might one day help people with hypertrophic cardiomyopathy, but human studies are needed first. If you have this condition, talk to your doctor about current treatment options
The Research Details
Scientists used mice that had a genetic mutation causing hypertrophic cardiomyopathy, a disease where the heart muscle grows too thick. They divided the mice into two groups: one received sotagliflozin mixed into their food at a dose of 30 milligrams per kilogram of food, while the other group ate regular food without the drug. The study lasted 8 weeks.
Throughout the study, researchers used ultrasound imaging to look at the mice’s hearts at the beginning, after 4 weeks, and after 8 weeks. This let them watch how the heart structure and function changed over time. At the end of the study, they examined the heart tissue under a microscope and tested how well the mitochondria (energy factories in cells) were working and how much oxidative stress (cellular damage from harmful molecules) was present.
The researchers compared the treated mice to untreated mice with the same genetic condition and to normal mice without the disease. This comparison helped them understand whether sotagliflozin actually made a difference.
This research approach matters because it shows what happens inside the heart at a detailed level. By studying mice with the exact same genetic mutation that causes human hypertrophic cardiomyopathy, scientists can understand how the disease develops and whether a treatment actually fixes the underlying problems, not just the symptoms. The combination of heart imaging, tissue examination, and molecular testing gives a complete picture of whether the drug works
This study was conducted in a controlled laboratory setting with standardized conditions, which makes the results reliable for understanding how the drug affects mice. However, mouse studies don’t always translate directly to humans because mice and humans have different body sizes, metabolisms, and genetic backgrounds. The study was published in a peer-reviewed journal, meaning other scientists reviewed the work before publication. The main limitation is that this is animal research, so human clinical trials are needed to confirm these findings are safe and effective in people
What the Results Show
Untreated mice with the genetic heart disease showed progressive worsening over 8 weeks: their hearts got thicker, scarring increased, and their heart’s ability to relax properly got worse. In contrast, mice treated with sotagliflozin showed remarkable improvement. The drug prevented further heart thickening, reduced the amount of scar tissue forming in the heart, and restored normal relaxation function. The treated mice’s atria (upper chambers of the heart) also shrank to more normal sizes.
At the cellular level, the drug fixed problems with mitochondria. In untreated diseased mice, the genes that control mitochondrial function were turned down or off, meaning the energy factories in heart cells weren’t working properly. Sotagliflozin turned these genes back on, restoring normal mitochondrial function. The drug also prevented the buildup of oxidative stress, which is cellular damage caused by harmful free radical molecules that accumulate in diseased hearts.
These improvements happened because sotagliflozin appears to work through multiple pathways. The drug belongs to a class called SGLT inhibitors, which affect how cells handle sodium and glucose. By changing these processes, the drug reduces the workload on heart cells and improves how mitochondria function, which in turn reduces oxidative stress and prevents the harmful remodeling that occurs in hypertrophic cardiomyopathy.
Interestingly, sotagliflozin did not reduce the upregulation of fibrosis genes in the diseased hearts. Fibrosis genes are responsible for scar tissue formation, and while the drug reduced actual scar tissue, it didn’t turn off the genes that promote scarring. This suggests the drug may work through a different mechanism to prevent scarring rather than by blocking the genetic signals for scar formation. This finding indicates that sotagliflozin’s benefits come primarily from improving mitochondrial function and reducing oxidative stress rather than from directly stopping the scarring process
Hypertrophic cardiomyopathy has long been known to involve problems with mitochondrial function and oxidative stress, but few treatments directly address these underlying issues. Most current treatments focus on managing symptoms like heart rhythm problems or reducing the heart’s workload. This study is notable because it shows that sotagliflozin, a drug originally developed for diabetes, may work on the root causes of the disease by restoring mitochondrial function. Previous research suggested SGLT inhibitors might help the heart, but this is one of the first studies showing they can correct the specific molecular problems in hypertrophic cardiomyopathy
The most important limitation is that this research was conducted only in mice, not humans. Mouse hearts are much smaller and work differently than human hearts, so results don’t automatically apply to people. The study didn’t test different doses of the drug to see if lower or higher amounts might work better. The researchers also didn’t follow the mice beyond 8 weeks, so it’s unknown whether the benefits continue long-term or if the disease eventually progresses despite treatment. Additionally, the study used mice with one specific genetic mutation (E180G), so it’s unclear whether sotagliflozin would help people with other genetic forms of hypertrophic cardiomyopathy or with non-genetic forms of the disease
The Bottom Line
This research suggests sotagliflozin may eventually become a treatment option for hypertrophic cardiomyopathy, but it’s too early to recommend it for patients. Human clinical trials are needed to confirm the drug is safe and effective in people. If you have hypertrophic cardiomyopathy, continue working with your cardiologist on current approved treatments. Stay informed about new clinical trials that may become available
People with hypertrophic cardiomyopathy and their families should follow this research, as it offers hope for new treatment options. Cardiologists and heart researchers should pay attention because this suggests a new approach to treating a serious genetic heart disease. People with diabetes taking SGLT inhibitors may also be interested in understanding how these drugs work at a cellular level
If sotagliflozin moves forward in human testing, it typically takes 5 to 10 years from successful animal studies to FDA approval for a new indication. Even if approved, it would take additional time for doctors to incorporate it into standard treatment plans. Patients should not expect this drug to become available for hypertrophic cardiomyopathy in the immediate future
Frequently Asked Questions
What is hypertrophic cardiomyopathy and why is it dangerous?
Hypertrophic cardiomyopathy is a genetic condition where the heart muscle becomes abnormally thick, making it harder for the heart to pump and relax properly. This can cause shortness of breath, chest pain, and dangerous heart rhythms that may lead to sudden cardiac death
How does sotagliflozin help hearts with this disease?
Sotagliflozin improves how mitochondria (cellular energy factories) work in heart cells and reduces oxidative stress (cellular damage from harmful molecules). By fixing these underlying problems, the drug prevents the heart from getting worse and restores normal heart function
When will sotagliflozin be available for patients with hypertrophic cardiomyopathy?
This mouse study is an early-stage discovery. Human clinical trials would need to happen first, which typically takes 5 to 10 years. There is no timeline yet for when or if this drug will be approved for this condition in humans
Can I ask my doctor about sotagliflozin for my heart condition?
You can discuss this research with your cardiologist, but sotagliflozin is not currently approved for hypertrophic cardiomyopathy. Your doctor can explain current treatment options and may inform you about clinical trials if they become available
Why do researchers test drugs in mice before trying them in humans?
Mouse studies help scientists understand how a drug works at the cellular level and whether it’s safe before testing in humans. Mice share about 95 percent of their genes with humans, making them useful for early research, but results don’t always translate directly to people
Want to Apply This Research?
- If you have hypertrophic cardiomyopathy, track your exercise tolerance (how far you can walk or how long you can exercise before feeling tired or short of breath) weekly using a simple 1-10 scale. This helps monitor whether any new treatments are improving your daily function
- Work with your doctor to establish a safe exercise routine and track it in the app. Even though this drug is experimental, maintaining appropriate physical activity as recommended by your cardiologist is important for heart health
- Set monthly reminders to check in with your cardiologist about any new research or clinical trials. Use the app to log any symptoms like shortness of breath, chest discomfort, or unusual fatigue to share with your healthcare team
This article describes research conducted in mice and does not represent approved medical treatment for humans. Hypertrophic cardiomyopathy is a serious genetic condition that requires ongoing care from a qualified cardiologist. Do not start, stop, or change any heart medications without consulting your doctor. If you have hypertrophic cardiomyopathy or a family history of this condition, work with your healthcare team to develop an appropriate treatment and monitoring plan. This research is preliminary and should not be used to make medical decisions
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.